Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
04 05 2022
Historique:
received: 08 12 2021
accepted: 07 04 2022
entrez: 4 5 2022
pubmed: 5 5 2022
medline: 7 5 2022
Statut: epublish

Résumé

As SARS-CoV-2 continues to spread and vaccines are rolled-out, the "double burden" of disparities in exposure and vaccination intersect to determine patterns of infection, immunity, and mortality. Serology provides a unique opportunity to measure prior infection and vaccination simultaneously. Leveraging algorithmically-selected residual sera from two hospital networks in the city of San Francisco, cross-sectional samples from 1,014 individuals from February 4-17, 2021 were each tested on two assays (Ortho Clinical Diagnostics VITROS Anti-SARS-CoV-2 and Roche Elecsys Anti-SARS-CoV-2), capturing the first year of the epidemic and early roll-out of vaccination. We estimated, using Bayesian estimation of infection and vaccination, that infection risk of Hispanic/Latinx residents was five times greater than of White residents aged 18-64 (95% Credible Interval (CrI): 3.2-10.3), and that White residents over 65 were twice as likely to be vaccinated as Black/African American residents (95% CrI: 1.1-4.6). We found that socioeconomically-deprived zipcodes had higher infection probabilities and lower vaccination coverage than wealthier zipcodes. While vaccination has created a 'light at the end of the tunnel' for this pandemic, ongoing challenges in achieving and maintaining equity must also be considered.

Identifiants

pubmed: 35508478
doi: 10.1038/s41467-022-30051-x
pii: 10.1038/s41467-022-30051-x
pmc: PMC9068757
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2451

Subventions

Organisme : NIAID NIH HHS
ID : K23 AI076614
Pays : United States
Organisme : NIA NIH HHS
ID : K24 AG046372
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI144048
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

© 2022. The Author(s).

Références

medRxiv. 2021 Mar 05;:
pubmed: 33688675
Vaccine. 2017 Feb 22;35(8):1167-1174
pubmed: 28126202
Clin Infect Dis. 2021 Nov 16;73(10):1784-1789
pubmed: 33560346
MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):431-436
pubmed: 33764963
Clin Infect Dis. 2021 Jul 30;73(Suppl 2):S127-S135
pubmed: 32821935
JAMA. 2021 Oct 12;326(14):1400-1409
pubmed: 34473201
Soc Sci Med. 2021 Mar;272:113638
pubmed: 33414032
PLoS One. 2021 Sep 20;16(9):e0257111
pubmed: 34543291
Ann Intern Med. 2020 Aug 4;173(3):233-234
pubmed: 32343767
Clin Infect Dis. 2021 Mar 1;72(5):e88-e95
pubmed: 33221832
Clin Infect Dis. 2021 Jul 15;73(2):324-327
pubmed: 32744615
Int J Equity Health. 2020 Jul 29;19(1):126
pubmed: 32727486
Nat Commun. 2021 Jun 11;12(1):3566
pubmed: 34117227
Soc Sci Med. 2017 Nov;193:70-79
pubmed: 29028558
Public Health. 2020 Jun;183:110-111
pubmed: 32502699
JAMA Netw Open. 2021 Oct 1;4(10):e2128575
pubmed: 34643719
Transl Behav Med. 2020 Aug 7;10(3):516-519
pubmed: 32542349
JAMA Netw Open. 2021 Oct 1;4(10):e2130343
pubmed: 34668949

Auteurs

Isobel Routledge (I)

Department of Medicine, University of California San Francisco, San Francisco, CA, USA. isobel.routledge@ucsf.edu.

Saki Takahashi (S)

Department of Medicine, University of California San Francisco, San Francisco, CA, USA. saki.takahashi@ucsf.edu.

Adrienne Epstein (A)

Department of Medicine, University of California San Francisco, San Francisco, CA, USA.

Jill Hakim (J)

Department of Medicine, University of California San Francisco, San Francisco, CA, USA.

Owen Janson (O)

Department of Medicine, University of California San Francisco, San Francisco, CA, USA.

Keirstinne Turcios (K)

Department of Medicine, University of California San Francisco, San Francisco, CA, USA.

Jo Vinden (J)

Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Infectious Disease and Immunity Graduate Group, University of California Berkeley, Berkeley, CA, USA.

John Tomas Risos (JT)

Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.

Margaret Rose Baniqued (MR)

Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.

Lori Pham (L)

Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.

Clara Di Germanio (C)

Vitalant Research Institute, San Francisco, CA, USA.

Michael Busch (M)

Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Vitalant Research Institute, San Francisco, CA, USA.

Margot Kushel (M)

Center for Vulnerable Populations, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, CA, USA.

Bryan Greenhouse (B)

Department of Medicine, University of California San Francisco, San Francisco, CA, USA.

Isabel Rodríguez-Barraquer (I)

Department of Medicine, University of California San Francisco, San Francisco, CA, USA. Isabel.rodriguez@ucsf.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH